α5-nAChR与MHC-I在肺腺癌中的表达及相关性

doi:10.6040/j.issn.1671-7554.0.2024.0061

摘要/Abstract

摘要： 目的探讨α5-烟碱型乙酰胆碱受体(alpha5-nicotinic acetylcholine receptor, α5-nAChR)与主要组织相容性复合体Ⅰ类分子(major histocompatibility complex class I molecule, MHC-I)在肺腺癌中的表达及相关性。方法 TCGA数据库分析CHRNA5(编码α5-nAChR基因)与HLA-B(编码MHC-I基因)在肺腺癌中的表达、相关性及其临床意义。运用免疫组织化学技术检测人肺腺癌临床样本、裸鼠肺腺癌异种移植瘤组织中α5-nAChR与MHC-I的表达及相关性。在人A549细胞、小鼠LLC细胞中,Western blotting检测在α5-nAChR不同表达水平下的FHIT与MHC-I表达及相关性。结果数据库分析表明,CHRNA5高表达或HLA-B低表达肺腺癌患者的生存率降低,CHRNA5与HLA-B的表达呈负相关(P<0.05)。α5-nAChR与MHC-I在人肺腺癌、裸鼠肺腺癌异种移植物中的表达呈负相关(P<0.05)。在肺腺癌细胞中,α5-nAChR的表达分别与FHIT、MHC-I的表达呈负相关(P<0.05),FHIT和MHC-I在肺腺癌细胞中的表达呈正相关(P<0.05)。结论 α5-nAChR与MHC-I的表达呈负相关,并参与肺腺癌的发生。

关键词: α5-烟碱型乙酰胆碱受体, 脆性组氨酸三联体, 主要组织相容性复合体I类分子, 肺腺癌, 相关性

Abstract: Objective To investigate the expression and correlation between alpha5-nicotinic acetylcholine receptor(α5-nAChR)and the major histocompatibility complex class I molecule(MHC-I)in lung adenocarcinoma. Methods TCGA database were used to study the expression, correlation, and clinical significance of encoding α5-nAChR gene(CHRNA5)and encoding MHC-I gene(HLA-B)in lung adenocarcinoma. The expressions of α5-nAChR and MHC-I were tested by immunohistochemistry staining in human lung adenocarcinoma specimans and nude mouse lung adenocarcinoma xenografts tissues. Furthermore, the expression and correlation of FHIT and MHC-I at different expression levels of α5-nAChR were detected by Western blotting in human A549 cells and mice LLC cells. Results Patients with lung adenocarcinoma with high expression of CHRNA5 or low expression of HLA-B had reduced survival, and CHRNA5 was negatively correlated with the expression of HLA-B(P<0.05). The expressions of α5-nAChR and MHC-I were negatively correlated in human lung adenocarcinoma and nude mouse lung adenocarcinoma xenografts tissues(P<0.05). In lung adenocarcinoma cells, the expression of α5-nAChR was negatively correlated with the expressions of FHIT and MHC-I, and the expression of FHIT and MHC-I was positively correlated(P<0.05). Conclusion The expressions of α5-nAChR and MHC-I are negatively correlated and involved in lung adenocarcinogenesis.

Key words: Alpha5-nicotinic acetylcholine receptor, Fragile histidine triad, Major histocompatibility complex class I molecule, Lung adenocarcinoma, Correlation

中图分类号:

R574

王靖婷,王璟,鲁艺,李静坦,李强,郏雁飞,马晓丽. α5-nAChR与MHC-I在肺腺癌中的表达及相关性[J]. 山东大学学报 (医学版), 2024, 62(5): 72-78.

WANG Jingting, WANG Jing, LU Yi, LI Jingtan, LI Qiang, JIA Yanfei, MA Xiaoli. Expression and correlation of α5-nAChR and MHC-I in lung adenocarcinoma[J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 72-78.

参考文献

[1] Mochizuki A, Shiraishi K, Honda T, et al. Passive smoking-induced mutagenesis as a promoter of lung carcinogenesis[J]. J Thorac Oncol, 2024: S1556-S0864(24)00074-1. doi:10.1016/j.jtho.2024.02.006.
[2] Liao KM, Shu CC, Liang FW, et al. Risk factors for pulmonary tuberculosis in patients with lung cancer: a retrospective cohort study[J]. J Cancer, 2023, 14(4): 657-664.
[3] He ZH, Xu YQ, Rao ZH, et al. The role of α7-nAChR-mediated PI3K/AKT pathway in lung cancer induced by nicotine[J]. Sci Total Environ, 2024, 912: 169604. doi:10.1016/j.scitotenv.2023.169604.
[4] Zhang Q, Jia Y, Pan P, et al. α5-nAChR associated with Ly6E modulates cell migration via TGF-β1/Smad signaling in non-small cell lung cancer[J]. Carcinogenesis, 2022, 43(4): 393-404.
[5] Shulepko MA, Bychkov ML, Shlepova OV, et al. Human secreted protein SLURP-1 abolishes nicotine-induced proliferation, PTEN down-regulation and α7-nAChR expression up-regulation in lung cancer cells[J]. Int Immunopharmacol, 2020, 82: 106303. doi:10.1016/j.intimp.2020.106303.
[6] Chen LS, Hung RJ, Baker T, et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis: a meta-analysis[J]. J Natl Cancer Inst, 2015, 107(5): djv100. doi:10.1093/jnci/djv100.
[7] 贾颖, 祖珊珊, 郏雁飞, 等. CHRNA5基因表达下调对肺癌细胞VEGF表达的影响[J]. 山东大学学报(医学版), 2014, 52(2): 12-15. JIA Ying, ZU Shanshan, JIA Yanfei, et al. Effect of down-regulated CHRNA5 gene expression on VEGF expression of lung cancer[J]. China Industrial Economics, 2014, 52(2): 12-15.
[8] Zhu P, Jin ZX, Kang GY, et al. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling[J]. Cell Commun Signal, 2022, 20(1): 121. doi:10.1186/s12964-022-00934-z.
[9] Jiao Y, Kang GY, Pan P, et al. Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via α5-nAChR/FHIT pathway[J]. Cell Mol Life Sci, 2023, 80(5): 119. doi:10.1007/s00018-023-04742-7.
[10] Niu ZY, Jiang DM, Shen JY, et al. Potential role of the fragile histidine triad in cancer evo-dev[J]. Cancers, 2023, 15(4): 1144. doi:10.3390/cancers15041144.
[11] Pulido M, Chamorro V, Romero I, et al. Restoration of MHC-I on tumor cells by fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine[J]. Cancers, 2020, 12(6): 1563. doi:10.3390/cancers12061563.
[12] Liu YE, Wang YJ, Yang YR, et al. Emerging phagocytosis checkpoints in cancer immunotherapy[J]. Signal Transduct Target Ther, 2023, 8(1): 104. doi:10.1038/s41392-023-01365-z.
[13] Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses[J]. Nat Rev Immunol, 2012, 12(12): 813-820.
[14] Yang S, Tang DF, Zhao YC, et al. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival[J]. Cancer Immunol Immunother, 2021, 70(10): 2819-2833.
[15] Ouspenskaia T, Law T, Clauser KR, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer[J]. Nat Biotechnol, 2022, 40(2): 209-217.
[16] Alsharairi NA. Quercetin derivatives as potential therapeutic agents: an updated perspective on the treatment of nicotine-induced non-small cell lung cancer[J]. Int J Mol Sci, 2023, 24(20): 15208. doi:10.3390/ijms242015208.
[17] 段依霜. 吸烟人群相关基因与肺癌发生发展的综述[J]. 实用预防医学, 2024, 31(3): 380-385. DUAN Yishuang. Review on genes related to smoking population and occurrence and development of lung cancer[J]. Practical Preventive Medicine, 2024, 31(3): 380-385.
[18] Alsharairi NA. Insights into the mechanisms of action of proanthocyanidins and anthocyanins in the treatment of nicotine-induced non-small cell lung cancer[J]. Int J Mol Sci, 2022, 23(14): 7905. doi:10.3390/ijms23147905.
[19] Kyte SL, Gewirtz DA. The influence of nicotine on lung tumor growth, cancer chemotherapy, and chemotherapy-induced peripheral neuropathy[J]. J Pharmacol Exp Ther, 2018, 366(2): 303-313.
[20] Romero I, Martinez M, Garrido C, et al. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells[J]. J Pathol, 2012, 227(3): 367-379.
[21] Mineur YS, Soares AR, Etherington IM, et al. Pathophysiology of nAChRs: limbic circuits and related disorders[J]. Pharmacol Res, 2023, 191: 106745. doi:10.1016/j.phrs.2023.106745.
[22] Liao YC, Cheng TC, Tu SH, et al. Tumor targeting and therapeutic assessments of RNA nanoparticles carrying α9-nAChR aptamer and anti-miR-21 in triple-negative breast cancers[J]. Mol Ther Nucleic Acids, 2023, 33: 351-366. doi:10.1016/j.omtn.2023.07.013.
[23] Li Q, Li JT, Wang JT, et al. PLEK2 mediates metastasis and invasion via α5-nAChR activation in nicotine-induced lung adenocarcinoma[J]. Mol Carcinog, 2024, 63(2): 253-265.
[24] Sari G, Rock KL. Tumor immune evasion through loss of MHC class-I antigen presentation[J]. Curr Opin Immunol, 2023, 83: 102329. doi:10.1016/j.coi.2023.102329.
[25] 李慧萍, 徐秀. 免疫分子MHC-Ⅰ在小鼠不同脑区的分布[J]. 复旦学报(医学版), 2021, 48(1): 41-46. LI Huiping, XU Xiu. Expression pattern of MHC-Ⅰ in different brain regions of mouse[J]. Fudan University Journal of Medical Sciences, 2021, 48(1): 41-46.
[26] da Silva IL, Montero-Montero L, Ferreira E, et al. New insights into the role of Qa-2 and HLA-G non-classical MHC-I complexes in malignancy[J]. Front Immunol, 2018, 9: 2894. doi:10.3389/fimmu.2018.02894.
[27] Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation[J]. Front Immunol, 2021, 12: 636568. doi:10.3389/fimmu.2021.636568.

相关文章 15

[1]	孟健丽,王庆港. 生物信息学方法探讨VPS72在肺腺/鳞癌中的表达及潜在作用机制[J]. 山东大学学报 (医学版), 2023, 61(8): 40-49.
[2]	杜圣红,李晓梅,陈晨,王玲. 鼻型弥漫大B细胞淋巴瘤合并肺腺癌1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(8): 111-115.
[3]	刘士标,张淑君,李培龙,杜鲁涛,王传新. cg20657709位点甲基化对肺腺癌早期诊断的初步探讨[J]. 山东大学学报 (医学版), 2023, 61(4): 18-25.
[4]	左安力,刘欣怡,郭子涵,蒋云秀,鲁德玕. 免疫球蛋白G4相关性疾病累及胸膜1例报告并文献复习[J]. 山东大学学报 (医学版), 2023, 61(12): 119-124.
[5]	赵启迪,王凯,赵小刚,闫涛,王亚东,杜贾军. 基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型[J]. 山东大学学报 (医学版), 2023, 61(10): 23-37.
[6]	洪慧,张卫海,李惠娴,李伟伟,张金岭. 异时性阑尾印戒细胞癌合并肺腺癌双原发癌1例[J]. 山东大学学报 (医学版), 2022, 60(8): 130-132.
[7]	刘丽雯,马俊,李沛铮,张秀芳,刘艺鸣. 128例帕金森病照料者负担及影响因素[J]. 山东大学学报 (医学版), 2022, 60(4): 45-49.
[8]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[9]	王静,刘粉,曾荣,黄思源,许长娟,梁子婷,董亮. 以胸膜病变为特征的IgG4相关性肺疾病1例[J]. 山东大学学报 (医学版), 2022, 60(3): 114-116.
[10]	高金梅,张向莲,刘铁菊. 血浆D-二聚体与109例膀胱癌中发生31例转移的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(3): 98-102.
[11]	张嘉豪,刘东旭. 70例不同垂直骨面型骨性Ⅱ类错牙合磨牙及基骨横向特征[J]. 山东大学学报 (医学版), 2021, 59(2): 76-82.
[12]	柴小雪,叶辉,吕欣然,丁续超,甄秋来,杜娟,曹莉莉. POU4F3表达对118例肺腺癌患者预后评估及对肺腺癌细胞株迁移的影响[J]. 山东大学学报 (医学版), 2021, 59(11): 8-18.
[13]	庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28.
[14]	杨秀婷,刘启功,左萍,刘正湘,左后娟. CD151-MUT突变对肺腺癌细胞A549迁移的影响及机制[J]. 山东大学学报 (医学版), 2020, 58(3): 81-86.
[15]	夏宇,陈任,陈菲,李伯阳,潘新锋,高翔,李程跃,徐凌忠. 2008~2017上海市居民健康素养时序变化与孕产妇及婴幼儿死亡率的相关性[J]. 山东大学学报 (医学版), 2019, 57(12): 97-102.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed